BCL2 and Granuloma: Excitingly, we found that inhibition of BCL-2 with the FDA approved ABT-199 along with MCL-1 inhibition with inhibitors in clinical trials and in the preclinical stage, significantly limits M.tb growth in human and murine macrophages, and a pre-clinical human granuloma model.